- Clinical characteristics by age group (N=66).
| Clinical features | Pediatrics (n=35) | Adults (n=31) | P-values |
|---|---|---|---|
| Male gender | 20 (57.1) | 15 (48.4) | 0.622 |
| Hospital-acquired infection | 27 (77.1) | 26 (83.9) | 0.549 |
| Previous hospitalization* | 22 (62.9) | 26 (83.9) | 0.095 |
| Previous ICU admission* | 16 (45.7) | 20 (64.5) | 0.751 |
| Respiratory disease | 15 (42.9) | 12 (38.7) | 0.805 |
| Cardiovascular disease | 18 (51.4) | 8 (25.8) | 0.045† |
| Previous infection* | 15 (42.9) | 23 (74.2) | 0.013† |
| Previous antimicrobial use* | 28 (80) | 27 (87.1) | 0.521 |
| Previous mechanical ventilation* | 16 (45.7) | 25 (80.6) | 0.005† |
| Colonized infection | 2 (5.7) | 3 (9.7) | 0.659 |
| Polymicrobial infection | 21 (60) | 21 (67.7) | 0.611 |
| Intubation* | 13 (37.1) | 19 (61.3) | 0.083 |
| Immunosuppressive therapy | 4 (11.4) | 16 (51.6) | 0.000† |
| Chemotherapy | 2 (5.7) | 5 (16.1) | 0.240 |
| Stem cell/solid organ transplant | 7 (20) | 13 (41.9) | 0.065 |
| Leukopenia | 6 (17.1) | 7 (22.6) | 0.758 |
| Anemia | 25 (71.4) | 29 (93.5) | 0.026† |
| Thrombocytopenia | 17 (48.6) | 15 (48.4) | 1.000 |
| Procalcitonin levels (>0.25 ng/mL) | 17 (48.6) | 18 (58.1) | 0.469 |
| C-reactive protein levels (>50 mg/L) | 9 (25.7) | 9 (29.0) | 0.789 |
| 28-day mortality | 5 (14.3) | 10 (32.3) | 0.140 |
| In-hospital mortality | 6 (17.1) | 17 (54.8) | 0.002† |